Taysha Gene Therapies Issues Equity Grants to Four New Hires
Taysha Gene Therapies awarded RSUs and stock options to four new employees under its 2023 Inducement Plan on Oct. 1, 2026.
Taysha Gene Therapies (Nasdaq: TSHA) disclosed Thursday that its Compensation Committee approved equity awards for four newly hired employees on October 1, 2026, as part of standard inducement compensation tied to their employment agreements.
The grants consist of restricted stock units representing 384,000 shares of Taysha common stock and a stock option covering 92,400 shares. Both awards were issued under the company's 2023 Inducement Plan, a vehicle specifically designed to attract new talent outside of shareholder-approved equity pools.
Read more Biogen's Litifilimab Shows Durable CLE Results at 52 Weeks →
The grants were structured to comply with Nasdaq Listing Rule 5635(c)(4), which permits companies to issue equity to new employees without prior shareholder approval when such awards serve as a material inducement to accept employment. Use of this rule is a common practice among clinical-stage biotechnology firms competing for specialized scientific and operational talent.
Dallas-based Taysha focuses on developing adeno-associated virus (AAV)-based gene therapies targeting severe monogenic diseases of the central nervous system. The company remains in the clinical stage, making equity compensation a key tool for recruiting personnel amid ongoing research and development operations.
Continue reading at GlobeNewswire - Industry News on Financial Services.
